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USING REGUMATE TO CONTROL ESTRUS IN SWINE
D. L. Davis

some ability to predict future occurrence of
estrus and plan for excesses and shortfalls in
the availability of gilts in a particular week.

Summary
Altrenogest, marketed for use in horses as
Regumate, is a synthetic progestin that is marketed for use in pigs as MATRIX. It effectively regulates the occurrence of estrus in
randomly cycling gilts if it is provided for 14
or more days at a daily dose of 15 mg/day. It
is important to assure that each gilt receives
her full dose; otherwise problems of cystic
follicles and reduced fertility may be observed.

Researchers began attempting to regulate
the estrous cycle of pigs at least 50 years ago.
The development of prostaglandin F2α products provided a method to regulate the estrous
cycle of several species of farm animals, but
not pigs. The mechanism of prostaglandin
products is to regress the corpora lutea (CL),
thus causing an early entry into proestrus, but
the pig CL are resistant to the effects of prostaglandin F2α until very late in their cycle and
a practical method to use them has not been
forthcoming. Some have inseminated gilts,
then used prostaglandin F2α to induce abortion followed by a fertile heat, but this is too
cumbersome for routine use.

(Key Words: Pigs, Estrous Synchronization,
Altrenogest.)
Introduction
It has long been recognized that gilts constitute a challenge for swine breeding herds.
Gilts are expensive, they occupy valuable
space, and the occurrence of estrus in gilts
may not fit the production schedule. Production managers often view gilts with skepticism, and most would opt for eliminating the
first pregnancy cycle and going right to the
second parity if there was a method to do it.

Soon after synthetic progestins became
available, there were many attempts to administer these to pigs as a part of the daily feed for
the purpose of estrous synchronization. To be
useful, the progestins should group the estruses of gilts at a reliable interval after the
end of progestin treatment, and provide fertility equal to untreated controls. Experiments
with these initial products revealed two things:

Gilts are unavoidable, however, and make
up 20 to 50% of breeding herds. The gilt pool
provides a management system to minimize
problems with gilt breedings, but the unpredictable occurrence of estrus in gilts creates
additional labor and housing costs. Many
production units opt for one or both of the following strategies: 1) house excess gilts to
make up for shortages on some weeks, 2)
check estrus but not breed at first detected estrus, thus allowing service to occur at a second
or later postpubertal estrus, and providing

1) with the progestins tested, a relatively
low dose would suppress estrus, but often resulted in follicular cysts, rather than the
growth of normal follicles and ovulation.
2) doses high enough to suppress the formation of follicular cysts led to poor synchronization of estrus and even lack of estrus.
Faulty sperm transport was also a problem.
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Among the initial progestins tested was
melengesterol acetate (MGA), a product used
to suppress estrus in feedlot heifers and as a
part of some synchronization protocols in cattle. Results of the earlier trials clearly indicate
that MGA will not be useful for synchronizing
estrus in pigs.

no. of gilts in estrus
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In the middle 1970s, the first experiments
were conducted at Abbott Laboratories with a
progestin that proved unique in its ability to
synchronize estruses in gilts. The progestin
has been identified by several names, including allyl trenbolone and altrenogest, and has
been marketed for use in horses as Regumate
for some time. Recently, Intervet, Inc. has
secured approval to market the formulation
long used in horses for use in pigs. The product, MATRIX, is supplied as a solution containing 0.22% (2.2 mg/mL) altrenogest. The
label indicates a treatment administering 6.8
mL (15 mg altrenogest) per gilt once daily for
14 consecutive days.

Control gilts
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Altrenogest-treated
gilts
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Figure 1. Occurrence of Estrus in Cycling
Gilts Not Treated (control) or Treated with
Altrenogest (15 mg/day) for 18 Days. Day 0
is the last day of altrenogest treatment.

Gilts should be treated on an individualanimal basis by top-dressing MATRIX on a
portion of each gilt's daily feed allowance.
The rest of this paper will describe the research leading to this recommendation and
will explain the mechanism of action of altrenogest for regulating estrous cycles in gilts.

Required Dose to Regulate Estrous
A well designed, two-stage study was
conducted at five locations in the United
States to identify the daily dose of altrenogest
required to synchronize estrus. Gilts that were
known to be having regular estrous cycles
were treated with increasing doses of altrenogest daily for 18 consecutive days. The data
indicated that daily doses less than 12.5
mg/day result in increased incidence of cystic
follicles. Many gilts with cysts at the lower
daily doses had multiple cysts and experienced failures to conceive.

Effectiveness of Altrenogest
When post-pubertal (cycling) gilts are
treated with altrenogest for 14 or 18 days, followed by cessation of altrenogest treatment,
there is a grouping of estruses between 4 and
10 days after the last altrenogest treatment.
The peak in occurrence of first estrus is generally from 5 to 7 days after last treatment. The
data in Figure 1 illustrate the estrous response
in cycling control gilts and those treated with
altrenogest. This response has proven to be
repeatable, and the estruses of 85% or more of
cycling gilts can be scheduled to a 5-day interval, with the majority of estruses occurring
in a 2- to 3-day interval.

These studies resulted in the recommendation that 15 mg/day be provided to each gilt to
provide a small margin of safety. Reliably
administering this dose requires treatment of
15

individual gilts. Attempts to feed altrenogest
to groups of gilts have met with poor synchrony of estrus, reduced numbers of gilts exhibiting estrus, and with reduced fertility.

The onset of estrus may be somewhat
more synchronous with the 18-day treatment
but for practical applications 14 days is adequate.

Recommended Duration of Treatment

Fertility After Altrenogest Treatment

The initial studies evaluated gilts provided
altrenogest for 18 days. In theory, however,
14 days should be adequate because the CL of
gilts regress on days 14 to 16 of their estrous
cycles. Comparison of 14- and 18-day durations of treatment is presented in Figure 2.

Numerous trials have evaluated the conception rate, farrowing rate, and litter size after treating gilts with altrenogest. The results
indicate no effects of altrenogest on these
traits. In some experiments there is a slight
improvement in litter size for altrenogesttreated gilts. This may result from the more
predictable time of estrus onset, and thus more
ideal timing of insemination. In some experiments ovulation rate is increased by altrenogest treatment but this has not been consistently observed.
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Altrenogest, the active ingredient in MATRIX, has been adequately evaluated in controlled experiments and field observation and,
if administered in a way that provides 15 mg
daily for 14 days, it is effective for regulating
the estruses of cycling gilts such that 85% or
more will express estrus 4 to 10 days after last
treatment with altrenogest.
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Figure 2. Effect on the Onset of Estrus of
Treating Gilts with Altrenogest (15 mg/day)
for 14 or 18 Days. The last day of altrenogest
treatment is day 0. (Drawn from data in Stevenson and Davis, J. Anim. Sci. 55:119-123,
1982).
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